Table 2. Incidence Rates for Alzheimer Disease and Related Dementia Across 4 Analysis Schemes.
| Exposure | Patients, No. | Outcomes | Person-years, No. | Follow-up time, median (IQR), d | Incidence rate per 1000 person-years (95% CI) |
|---|---|---|---|---|---|
| Tofacitinib vs abatacept | |||||
| Analysis 1a | |||||
| Tofacitinib | 4224 | 29 | 3452 | 171 (59-396) | 8.4 (5.6-12.1) |
| Abatacept | 4224 | 38 | 3966 | 199 (88-467) | 9.6 (6.8-13.2) |
| Analysis 2b | |||||
| Tofacitinib | 2164 | 47 | 3363 | 531 (230-905) | 14.0 (10.3-18.6) |
| Abatacept | 2164 | 63 | 3481 | 568 (244-954) | 18.1 (13.9-23.2) |
| Analysis 3c | |||||
| Tofacitinib | 2053 | 25 | 2014 | 226 (96-525) | 12.4 (8.0-18.3) |
| Abatacept | 2053 | 20 | 2065 | 240 (89-553) | 9.7 (5.9-15) |
| Analysis 4d | |||||
| Tofacitinib | 4224 | <11 | 3469 | 172 (59-397) | 2.0 (0.8-4.2) |
| Abatacept | 4224 | 17 | 3986 | 201 (88-471) | 4.3 (2.5-6.8) |
| Tocilizumab vs abatacept | |||||
| Analysis 1a | |||||
| Tocilizumab | 6369 | 44 | 7002 | 216 (89-539) | 6.3 (4.6-8.4) |
| Abatacept | 6369 | 58 | 7451 | 235 (102-574) | 7.8 (5.9-10.1) |
| Analysis 2b | |||||
| Tocilizumab | 3949 | 121 | 7867 | 825 (393-1095) | 15.4 (12.8-18.4) |
| Abatacept | 3949 | 116 | 7874 | 838 (377-1095) | 14.7 (12.2-17.7) |
| Analysis 3c | |||||
| Tocilizumab | 3489 | 36 | 4548 | 301 (112-686) | 7.9 (5.5-11.0) |
| Abatacept | 3489 | 31 | 4676 | 304 (104-699) | 6.6 (4.5-9.4) |
| Analysis 4 | |||||
| Tocilizumabd | 6369 | 20 | 7022 | 216 (89-540) | 2.9 (1.7-4.4) |
| Abatacept | 6369 | 28 | 7486 | 235 (103-579) | 3.7 (2.5-5.4) |
| TNFI vs abatacept | |||||
| Analysis 1a | |||||
| TNFI | 11 976 | 113 | 15 340 | 237 (83-603) | 7.4 (6.1-8.9) |
| Abatacept | 11 976 | 128 | 16 130 | 247 (103-631) | 7.9 (6.6-9.4) |
| Analysis 2b | |||||
| TNFI | 7940 | 274 | 17 408 | 1095 (485-1095) | 15.7 (13.9-17.7) |
| Abatacept | 7940 | 270 | 17 435 | 1095 (495-1095) | 15.5 (13.7-17.5) |
| Analysis 3c | |||||
| TNFI | 7117 | 106 | 11 068 | 329 (127-764) | 9.6 (7.8-11.6) |
| Abatacept | 7117 | 99 | 11 490 | 344 (115-808) | 8.6 (7-10.5) |
| Analysis 4d | |||||
| TNFI | 11 976 | 41 | 15 405 | 237 (83-606) | 2.7 (1.9-3.6) |
| Abatacept | 11 976 | 48 | 16 226 | 249 (103-635) | 3.0 (2.2-3.9) |
Abbreviation: TNFI, tumor necrosis factor inhibitor.
a
Analysis 1 was an as-treated follow-up approach.
b
Analysis 2 was an as-started follow-up approach incorporating a 6-month induction period.
c
Analysis 3 incorporated a 6-month symptom to diagnosis period.
d
Analysis 4 used an alternate outcome definition.